Lifecore Biomedical (NASDAQ:LFCR) Issues Earnings Results

Lifecore Biomedical (NASDAQ:LFCR) released its quarterly earnings results on Wednesday. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.24) by ($0.19), FiscalAI reports. Lifecore Biomedical had a negative return on equity of 1,211.09% and a negative net margin of 23.08%.The business had revenue of $23.19 million during the quarter, compared to the consensus estimate of $25.96 million.

Here are the key takeaways from Lifecore Biomedical’s conference call:

• Reaffirmed 2026 guidance and mid‑term targets — Lifecore reiterated 2026 revenue guidance of $120–125M and adjusted EBITDA of $20.5–25M, and reiterated a goal of 12% revenue CAGR and >25% EBITDA margin by end of 2029.
• Q1 results disappointed — revenue fell 34% year‑over‑year to $23.2M, gross profit declined and the company reported a $15M net loss with adjusted EBITDA of $1M, driven by front‑loaded headwinds and timing shifts.
• Notable business development wins — signed three commercial site‑transfer/CDMO agreements (including an aesthetics onshore transfer and two programs with a U.S. biopharma customer) and expanded a late‑stage pipeline, with these transfers expected to be commercial by 2028 and represent mid‑seven‑figure opportunities each.
• Expense cuts and stronger liquidity — SG&A and R&D reduced by nearly $8M since late‑2024, fifth consecutive quarter of positive operating cash flow, and ending Q1 liquidity of ~ $38M (~$21M cash + ~$17M revolver availability).
• Operational and quality progress — ERP implementation went smoothly in January, multiple customer inspections had positive outcomes, and the company is preparing to support a planned doubling of its largest customer’s commercial demand beginning in 2027.

Lifecore Biomedical Trading Down 3.9%

NASDAQ:LFCR traded down $0.20 during mid-day trading on Wednesday, reaching $4.96. 221,757 shares of the stock were exchanged, compared to its average volume of 270,751. The business has a fifty day moving average price of $5.29 and a 200 day moving average price of $6.83. The firm has a market capitalization of $185.90 million, a PE ratio of -5.06 and a beta of 1.08. Lifecore Biomedical has a 1-year low of $3.63 and a 1-year high of $8.98.

Hedge Funds Weigh In On Lifecore Biomedical

Large investors have recently made changes to their positions in the business. Rhumbline Advisers raised its holdings in shares of Lifecore Biomedical by 54.0% in the 2nd quarter. Rhumbline Advisers now owns 38,091 shares of the company’s stock worth $309,000 after purchasing an additional 13,361 shares in the last quarter. Wells Fargo & Company MN boosted its holdings in Lifecore Biomedical by 69.7% during the fourth quarter. Wells Fargo & Company MN now owns 30,757 shares of the company’s stock worth $252,000 after buying an additional 12,632 shares in the last quarter. Boothbay Fund Management LLC acquired a new position in Lifecore Biomedical in the third quarter worth approximately $221,000. PharVision Advisers LLC acquired a new position in Lifecore Biomedical in the third quarter worth approximately $151,000. Finally, Price T Rowe Associates Inc. MD increased its holdings in shares of Lifecore Biomedical by 20.4% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 16,646 shares of the company’s stock valued at $137,000 after buying an additional 2,826 shares in the last quarter. Institutional investors own 83.36% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts recently issued reports on LFCR shares. Barrington Research increased their target price on shares of Lifecore Biomedical from $5.50 to $6.00 and gave the company an “outperform” rating in a research report on Wednesday, April 29th. Weiss Ratings reiterated a “sell (d)” rating on shares of Lifecore Biomedical in a report on Tuesday, April 21st. Two investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $6.00.

Lifecore Biomedical Company Profile

Lifecore Biomedical, Inc is a publicly traded specialty biopharmaceutical company headquartered in Chaska, Minnesota. The company focuses on the development, manufacture and commercialization of hyaluronic acid (HA)–based products that address medical and aesthetic needs. Lifecore’s proprietary HA formulations are designed to meet strict regulatory standards for purity, consistency and performance in highly regulated markets.

The company’s product portfolio spans multiple therapeutic areas, including ophthalmology, orthopedics, dermatology and wound care.